Vandenbark et al., 2008 - Google Patents
Critical evaluation of regulatory T cells in autoimmunity: are the most potent regulatory specificities being ignored?Vandenbark et al., 2008
View PDF- Document ID
- 3728185175169636314
- Author
- Vandenbark A
- Offner H
- Publication year
- Publication venue
- Immunology
External Links
Snippet
The identification of CD4+ CD25+ Foxp3+ regulatory T (Treg) cells as natural regulators of immunity in the periphery and tissues has stimulated tremendous interest in developing therapeutic strategies for autoimmune diseases. In this review, the site of origin, antigen …
- 210000003289 regulatory T cell 0 title abstract description 209
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sakaguchi et al. | Regulatory T cells and immune tolerance | |
| Horton et al. | Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non–small cell lung cancer | |
| Vandenbark et al. | Critical evaluation of regulatory T cells in autoimmunity: are the most potent regulatory specificities being ignored? | |
| Liberal et al. | Regulatory T cells: mechanisms of suppression and impairment in autoimmune liver disease | |
| Chiba et al. | Mucosal‐associated invariant T cells promote inflammation and exacerbate disease in murine models of arthritis | |
| Martin‐Orozco et al. | Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells | |
| Grazia Roncarolo et al. | Interleukin‐10‐secreting type 1 regulatory T cells in rodents and humans | |
| Sojka et al. | Mechanisms of regulatory T‐cell suppression–a diverse arsenal for a moving target | |
| Lee et al. | Progesterone suppresses the m TOR pathway and promotes generation of induced regulatory T cells with increased stability | |
| Boissonnas et al. | Foxp3+ T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes | |
| Gol-Ara et al. | The role of different subsets of regulatory T cells in immunopathogenesis of rheumatoid arthritis | |
| Lohr et al. | Regulatory T cells in the periphery | |
| Stephens et al. | Curing CNS autoimmune disease with myelin‐reactive Foxp3+ Treg | |
| Francis et al. | Induction of transplantation tolerance converts potential effector T cells into graft‐protective regulatory T cells | |
| Huynh et al. | Signals and pathways controlling regulatory T cells | |
| Moreau et al. | Transitional‐2 B cells acquire regulatory function during tolerance induction and contribute to allograft survival | |
| Raha et al. | Disruption of de novo fatty acid synthesis via acetyl‐CoA carboxylase 1 inhibition prevents acute graft‐versus‐host disease | |
| Cobbold et al. | Regulatory cells and transplantation tolerance | |
| Qiao et al. | CD4+ CD5+ regulatory T cells render naive CD4+ CD25–T cells anergic and suppressive | |
| Kapp et al. | CD8+ suppressor T cells resurrected | |
| Porter et al. | Characterization and expansion of baboon CD4+ CD25+ Treg cells for potential use in a non‐human primate xenotransplantation model | |
| Meehan et al. | Preclinical models of arthritis for studying immunotherapy and immune tolerance | |
| Kapp et al. | TCR transgenic CD8+ T cells activated in the presence of TGFβ express FoxP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection | |
| Mencarelli et al. | Calcineurin-mediated IL-2 production by CD11chighMHCII+ myeloid cells is crucial for intestinal immune homeostasis | |
| Dieckmann et al. | Activated CD4+ CD25+ T cells suppress antigen‐specific CD4+ and CD8+ T cells but induce a suppressive phenotype only in CD4+ T cells |